Abstract
Research on the human urine proteome may lay the foundation for the discovery of relevant disease biomarkers. Posttranslational modifications (PTMs) have important effects on the functions of protein biomarkers. Identifying PTMs without enrichment adds no extra steps to conventional identification procedures for urine proteomics. The only difference is that this method requires software that can conduct unrestrictive identifications of PTMs. These PTMs include methylation, dehydration, oxidation, hydroxylation, phosphorylation, or dihydroxylation. These data are useful reference for PTM biomarker discovery in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rossing K, Mischak H, Rossing P et al (2008) The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2:997–1007
Ahmed N, Hornalley PJT, Adidi RJ et al (2005) Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 28:2465–2471
Vivekanandan Giri A, Slocum JL, Buller CL et al (2011) Urine glycoprotein profile reveals novel Markers for chronic kidney disease. Int J Proteomics, 214715
Christensen B, Petersen TE, Sørensen ES (2008) Posttranslational modification and proteolytic processing of urinary osteopontin. Biochem Soc 411:53–61
Ye B, Skates S, Mok SC et al (2006) Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12:432–441
Thongboonkerd V, Arthur JM, Klein JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62:1461–1469
Kiernan UA, Tubbs KA, Nedelkov D et al (2003) Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res 2:191–197
Wang L, Li F, Sun W et al (2006) Concanavalin A-captured glycoproteins in healthy human urine. Mol Cell Proteomics 5:560–562
Moon PG, Hwang HH, Boo YC et al (2008) Proteomics and 2-DE identification of rat urinary glycoproteome captured by three lectins using gel and LC-based proteomics. Electrophoresis 29:4324–4331
Halim A, Nilsson J, Rüetschi U et al (2012) Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD. Mol Cell Proteomics 11:M111.013649
Zhao Y, Jensen ON (2009) Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques. Proteomics 9:4632–4641
Li QR, Fan KX, Li RX et al (2010) A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine. Rapid Commun Mass Spectrom 24:823–832
Na S, Bandeira N, Paek E (2012) Fast multi-blind modification search through tandem mass spectrometry. Mol Cell Proteomics 11:M111.010199
Han X, He L, Xi L et al (2011) PeaksPTM: mass spectrometry-based identification of peptides with unspecified modifications. J Proteome Res 10:2930–2936
Liu L, Liu X, Sun W et al (2013) Unrestrictive identification of post-translational modifications in the urine proteome without enrichment. Proteome Science 11:1
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Liu, L., Liu, X. (2015). Urinary Proteins with Post-translational Modifications. In: Gao, Y. (eds) Urine Proteomics in Kidney Disease Biomarker Discovery. Advances in Experimental Medicine and Biology, vol 845. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9523-4_6
Download citation
DOI: https://doi.org/10.1007/978-94-017-9523-4_6
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-9522-7
Online ISBN: 978-94-017-9523-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)